Latest & greatest articles for proton pump inhibitors

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on proton pump inhibitors or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on proton pump inhibitors and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for proton pump inhibitors

81. Potassium-competitive acid blockers versus proton-pump inhibitors in endoscopic submucosal dissection-induced gastric ulcers: a systematic review and meta-analysis

Potassium-competitive acid blockers versus proton-pump inhibitors in endoscopic submucosal dissection-induced gastric ulcers: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g

2017 PROSPERO

82. Efficacy and safety of proton pump inhibitors to treat GER in neonates

Efficacy and safety of proton pump inhibitors to treat GER in neonates Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web address: Timing and effect

2017 PROSPERO

83. Co-administration of proton pump inhibitors and metformin: a systematic review

Co-administration of proton pump inhibitors and metformin: a systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web address: Timing and effect

2017 PROSPERO

84. Effectiveness of interventions to deprescribe inappropriate proton pump inhibitors in older adults.

Effectiveness of interventions to deprescribe inappropriate proton pump inhibitors in older adults. Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web

2017 PROSPERO

85. Proton Pump Inhibitors (PPIs): Is Perpetual Prescribing Inevitable?

Proton Pump Inhibitors (PPIs): Is Perpetual Prescribing Inevitable? Tools for Practice is proudly sponsored by the Alberta College of Family Physicians (ACFP). ACFP is a provincial, professional voluntary organization, representing more than 4,500 family physicians, family medicine residents, and medical students in Alberta. Established over sixty years ago, the ACFP strives for excellence in family practice through advocacy, continuing medical education and primary care research. www.acfp.ca (...) June 26, 2017 Proton Pump Inhibitors (PPIs): Is Perpetual Prescribing Inevitable? Clinical Question: How successful are attempts to stop PPIs and how can clinicians improve chances of success? Bottom Line: Using a range of deprescribing strategies, about 25% of patients with gastroesophageal reflux disease (GERD) or dyspepsia can stop PPI use and another 30-50% can decrease their dose. Older patients and those who taper appear more successful in stopping PPIs. Evidence: • Clustered randomized

2017 Tools for Practice

86. Community acquired pneumonia incidence before and after proton pump inhibitor prescription: population based study. Full Text available with Trip Pro

Community acquired pneumonia incidence before and after proton pump inhibitor prescription: population based study. Objective To examine the risk of community acquired pneumonia before and after prescription of proton pump inhibitor (PPI) and assess whether unmeasured confounding explains this association.Design Cohort study and self controlled case series.Setting Clinical Practice Research Datalink (1990 to 2013) in UK.Participants Adult patients with a new prescription for a PPI individually

2016 BMJ

87. A systematic review of the comparative effectiveness of proton pump inhibitors for the treatment of adult patients with gastroesophageal reflux disease or peptic ulcer disease

A systematic review of the comparative effectiveness of proton pump inhibitors for the treatment of adult patients with gastroesophageal reflux disease or peptic ulcer disease A systematic review of the comparative effectiveness of proton pump inhibitors for the treatment of adult patients with gastroesophageal reflux disease or peptic ulcer disease | Therapeutics Initiative Independent Healthcare Evidence > > A systematic review of the comparative effectiveness of proton pump inhibitors (...) for the treatment of adult patients with gastroesophageal reflux disease or peptic ulcer disease This was produced by the Drug Assessment Working Group of the Therapeutics Initiative at the request of the Pharmaceutical Services Division (PSD) of the British Columbia Ministry of Health as part of the Drug Effectiveness Review Project (DERP), a class review of proton pump inhibitors (PPIs) for the treatment of adult patients with symptomatic GERD or PUD. Research questions Four research questions were

2016 Therapeutics Letter

88. Comparative effectiveness of proton pump inhibitors

Comparative effectiveness of proton pump inhibitors March - April 2016 99 © Mailing Address: Therapeutics Initiative The University of British Columbia Department of Anesthesiology, Pharmacology & Therapeutics 2176 Health Sciences Mall Vancouver, BC Canada V6T 1Z3 Comparative effectiveness of proton pump inhibitors Comparative trials of PPIs in adult patients with symptomatic PUD Based on 6 RCTs in 1753 patients, esomeprazole was not significantly different from other PPIs for most outcome (...) proton pump inhibitors (PPIs). 1-6 These drugs work by irreversibly inhibiting gastric H+K+ ATPase (the proton pump) in the stomach. They inhibit both basal and stimulated acid secretion and are used in a number of clinical set- tings: gastroesophageal reflux disease (GERD), reflux esophagitis, peptic ulcer disease (PUD), and symptoms associated with stomach acid such as heartburn and acid indigestion. Are there any important differences between the different drugs in the class? We have conducted two

2016 Therapeutics Letter

89. Meta-analysis of the efficacy of proton pump inhibitors for the symptoms of laryngopharyngeal reflux. Full Text available with Trip Pro

Meta-analysis of the efficacy of proton pump inhibitors for the symptoms of laryngopharyngeal reflux. The objective of this study was to perform a systematic review and meta-analysis to assess the effectiveness of proton pump inhibitors (PPI) for reflux disease in adult patients with laryngopharyngeal symptoms. A comprehensive search of Cochrane Library, EMBASE, Ovid EBM Reviews, and PubMed was performed for English-language literature about laryngopharyngeal reflux (LPR), in September 2014

2016 Brazilian journal of medical and biological research = Revista brasileira de pesquisas médicas e biológicas / Sociedade Brasileira de Biofísica ... [et al.]

90. Rapid and ultra-rapid metabolizers with CYP2C19*17 polymorphism do not respond to standard therapy with proton pump inhibitors Full Text available with Trip Pro

Rapid and ultra-rapid metabolizers with CYP2C19*17 polymorphism do not respond to standard therapy with proton pump inhibitors Polymorphisms in genes encoding drug metabolizing enzymes may lead to varied enzyme activity and inter-individual variability in drug efficacy and/or toxicity. Since CYP2C19 and CYP3A4 genes code for enzymes involved in metabolizing wide variety of drugs including proton pump inhibitors, we sought to identify polymorphisms in these genes in order to study their impact (...) on drug metabolism in subjects.DNA was isolated from healthy individuals including tribals and genotyped for 11 single nucleotide polymorphisms in CYP2C19 and 6 polymorphisms in CYP3A4. Individuals were categorized into different phenotypes based on their drug metabolizing genotype. Volunteers from each group were administered proton pump inhibitors (Esomeprazole, Pantoprazole; 40 mg/day) for 5 days followed by pharmacokinetic studies and measurement of intra-gastric pH.Of the 17 polymorphisms studied

2016 Meta gene

91. [Comment on “Individual Proton Pump Inhibitors and Outcomes in Patients With Coronary Artery Disease on Dual Antiplatelet Therapy: A Systematic Review”]. (Abstract)

[Comment on “Individual Proton Pump Inhibitors and Outcomes in Patients With Coronary Artery Disease on Dual Antiplatelet Therapy: A Systematic Review”]. 27218125 2016 08 24 2018 12 02 2174-2030 35 1 2016 Jan Revista portuguesa de cardiologia : orgao oficial da Sociedade Portuguesa de Cardiologia = Portuguese journal of cardiology : an official journal of the Portuguese Society of Cardiology Rev Port Cardiol [Comment on “Individual Proton Pump Inhibitors and Outcomes in Patients (...) With Coronary Artery Disease on Dual Antiplatelet Therapy: A Systematic Review”]. 71-2 Mimoso Jorge J por Journal Article Comment Comentário a «Efeitos dos inibidores da bomba de protões em doentes com doença arterial coronária sob dupla antiagregação plaquetar: uma revisão sistemática» . Portugal Rev Port Cardiol 8710716 0870-2551 0 Platelet Aggregation Inhibitors 0 Proton Pump Inhibitors OM90ZUW7M1 Ticlopidine R16CO5Y76E Aspirin IM J Am Heart Assoc. 2015 Nov;4(11). pii: e002245. doi: 10.1161/JAHA

2016 Revista portuguesa de cardiologia : orgão oficial da Sociedade Portuguesa de Cardiologia = Portuguese journal of cardiology : an official journal of the Portuguese Society of Cardiology

92. Drug-Induced Subacute Cutaneous Lupus Erythematosus Associated with Proton Pump Inhibitors Full Text available with Trip Pro

Drug-Induced Subacute Cutaneous Lupus Erythematosus Associated with Proton Pump Inhibitors Subacute cutaneous lupus erythematosus (SCLE) is an autoimmune disease that may be induced by proton pump inhibitors (PPIs) in at-risk populations. The US FDA does not recognize SCLE as an adverse event associated with PPIs. We queried the FDA Adverse Event Reporting System database, which contains adverse event case reports submitted by the public as well as by industry, and analyzed the data to quantify

2016 Drugs - real world outcomes

93. Pre-Endoscopic Intravenous Proton Pump Inhibitors for Emergency Department Patients with Upper Gastrointestinal Bleeds: A Review of Clinical Effectiveness, Cost-Effectiveness and Guidelines

Pre-Endoscopic Intravenous Proton Pump Inhibitors for Emergency Department Patients with Upper Gastrointestinal Bleeds: A Review of Clinical Effectiveness, Cost-Effectiveness and Guidelines Pre-Endoscopic Intravenous Proton Pump Inhibitors for Emergency Department Patients with Upper Gastrointestinal Bleeds: A Review of Clinical Effectiveness, Cost-Effectiveness and Guidelines | CADTH.ca Find the information you need Pre-Endoscopic Intravenous Proton Pump Inhibitors for Emergency Department (...) Patients with Upper Gastrointestinal Bleeds: A Review of Clinical Effectiveness, Cost-Effectiveness and Guidelines Pre-Endoscopic Intravenous Proton Pump Inhibitors for Emergency Department Patients with Upper Gastrointestinal Bleeds: A Review of Clinical Effectiveness, Cost-Effectiveness and Guidelines Published on: February 5, 2016 Project Number: RC0740-000 Product Line: Research Type: Drug Report Type: Summary with Critical Appraisal Result type: Report Question What is the clinical effectiveness

2016 Canadian Agency for Drugs and Technologies in Health - Rapid Review

94. Concern for Myocardial Infarction Risk Associated with Proton Pump Inhibitor Use in Patients With No Underlying Cardiovascular Disease

Concern for Myocardial Infarction Risk Associated with Proton Pump Inhibitor Use in Patients With No Underlying Cardiovascular Disease "Concern for Myocardial Infarction Risk Associated with Proton Pump Inh" by Natasha K. Ludwig < > > > > > Title Author Date of Graduation Fall 8-13-2016 Degree Type Capstone Project Degree Name Master of Science in Physician Assistant Studies First Advisor Saje Davis-Risen, PA-C, MS Second Advisor Annjanette Sommers, PA-C, MS Rights . Abstract Background: Proton (...) . The purpose of this review is to explore if PPI use is associated with an increased MI risk in patients with no underlying cardiovascular disease. Methods: An exhausted search of available medical literature was performed using MEDLINE-Ovid, MEDLINE-Pubmed, Web of Science, and CINAHL using the keywords proton pump inhibitors, myocardial infarction, and epidemiology. Relevant articles were assessed for validity using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) system

2016 Pacific University EBM Capstone Project

95. Do inpatients receiving proton pump inhibitors (PPIs) have a higher risk of Clostridium difficile infections (CDIs)?

Do inpatients receiving proton pump inhibitors (PPIs) have a higher risk of Clostridium difficile infections (CDIs)? Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence

2016 PROSPERO

96. Review of long term use of proton pump inhibitor in association with vitamin B12 deficiency

Review of long term use of proton pump inhibitor in association with vitamin B12 deficiency Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web address

2016 PROSPERO

97. Systematic review and meta-analysis of the effect of proton-pump inhibitors (PPI) on the risk of small intestinal bacterial overgrowth

Systematic review and meta-analysis of the effect of proton-pump inhibitors (PPI) on the risk of small intestinal bacterial overgrowth Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne

2016 PROSPERO

98. Proton pump inhibitors use and the risk of chronic kidney disease: a systematic review

Proton pump inhibitors use and the risk of chronic kidney disease: a systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web address: Timing

2016 PROSPERO

99. Dementia and cognitive impairment risk with proton pump inhibitor therapy: a systematic review

Dementia and cognitive impairment risk with proton pump inhibitor therapy: a systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web address

2016 PROSPERO

100. Cardiovascular risk with proton pump inhibitor therapy: systematic review and meta-analysis

Cardiovascular risk with proton pump inhibitor therapy: systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web address

2016 PROSPERO